Establishment Labs Holdings Inc
F:3E0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Establishment Labs Holdings Inc
F:3E0
|
CR |
|
S
|
SMCG Co Ltd
KOSDAQ:460870
|
KR |
Establishment Labs Holdings Inc
Establishment Labs makes medical devices for breast reconstruction and cosmetic breast surgery. Its main products are breast implants, tissue expanders, and the tools surgeons use to place and size those implants. The company is best known for the Motiva implant line, which it sells into the breast aesthetics and reconstruction market. Its customers are plastic surgeons, hospitals, and surgical clinics that perform breast procedures. Establishment Labs makes money by selling implants and related surgical products, usually through distributors and direct sales teams, to providers who use them in the operating room. In this business, the company sits close to the end of the medical device value chain, because it sells finished implants rather than raw materials or general-purpose equipment. What makes the business model distinct is its narrow focus. Instead of selling a broad range of hospital devices, it concentrates on one surgical category where product design, surgeon training, and clinical confidence matter a lot. That gives the company a specialized role in aesthetic and reconstructive breast surgery, where surgeons often choose brands based on safety features, feel, and implant handling.
Establishment Labs makes medical devices for breast reconstruction and cosmetic breast surgery. Its main products are breast implants, tissue expanders, and the tools surgeons use to place and size those implants. The company is best known for the Motiva implant line, which it sells into the breast aesthetics and reconstruction market.
Its customers are plastic surgeons, hospitals, and surgical clinics that perform breast procedures. Establishment Labs makes money by selling implants and related surgical products, usually through distributors and direct sales teams, to providers who use them in the operating room. In this business, the company sits close to the end of the medical device value chain, because it sells finished implants rather than raw materials or general-purpose equipment.
What makes the business model distinct is its narrow focus. Instead of selling a broad range of hospital devices, it concentrates on one surgical category where product design, surgeon training, and clinical confidence matter a lot. That gives the company a specialized role in aesthetic and reconstructive breast surgery, where surgeons often choose brands based on safety features, feel, and implant handling.
Revenue: Establishment Labs reported first-quarter revenue of $59.9 million, up 44.7% from last year, with especially strong growth in the U.S. business.
Profitability: Gross margin improved to 70.7%, adjusted EBITDA was $1.2 million, and this was the third straight quarter of positive adjusted EBITDA.
U.S. momentum: U.S. revenue reached $19.6 million, up 216% year over year and 13.3% sequentially, supported by both broader Motiva adoption and the new minimally invasive launch.
Outlook raised: Management lifted full-year revenue guidance to $266.5 million to $268.5 million from $264 million to $266 million and now expects minimally invasive revenue to exceed $35 million.
Cash path: The company said it refinanced its debt, has enough cash to reach cash flow positive in the second half of the year, and does not plan to raise equity.
Product strategy: Management emphasized that Preserve and Mia are expanding the market rather than cannibalizing it, with early signs of premium pricing, faster surgeon adoption, and new patients entering the category.
